What is CLDI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CLDI?

P/E (TTM) is n/a and 52-week range is $0.99 to $27.84 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CLDI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CLDI?

The company profile lists net income (TTM) near $-1.23B, EPS (TTM) near $-63.54 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Calidi Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 19.3M shares outstanding, ISIN US3207034089 when available from company profile and filing metadata.

Calidi Biotherapeutics Inc

$CLDI

Health Care · Biotechnology

IR Run Scenarios

$1.03

-0.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company is headquartered in San Diego, California and currently employs 29 full-time employees. The company went IPO on 2021-09-10. The firm is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. The company is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.

Employees

Website

www.calidibio.com/

IPO

2021-09-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)